Efficacy and safety of low-dose telitacicept in IgA nephropathy: a real-world study.
- 1Department of Nephrology, Hunan Key Laboratory of Kidney Disease and Blood Purification, The Second Xiangya Hospital, Central South University, Changsha, China.
- 2Department of Geriatrics, The Second Xiangya Hospital, Central South University, Changsha, China.
Abstract
Background
Immunoglobulin A nephropathy (IgAN) represents one of the most common causes of primary glomerulonephritis with unmet clinical needs. This study evaluates the efficacy and safety of telitacicept in patients with IgAN.Methods
This real-world study included 38 biopsy-proven IgAN patients with baseline estimated glomerular filtration rate (eGFR) >10 mL/min/1.73 m² and urine protein-to-creatinine ratio (UPCR) >440 mg/g. Nineteen patients received weekly telitacicept 80 mg (telitacicept group), divided into early-start (telitacicept treatment initiated within 6 months after diagnosis) and late-start (>6 months) subgroups. The other 19, diagnosed during the same period but not receiving telitacicept, served as controls. Clinical data were collected over 12 months. Safety was evaluated.Results
Baseline characteristics were comparable between groups. In the telitacicept group, median UPCR was 1715.98 mg/g (interquartile range 1281.63-2892.11) and median eGFR was 45.45 mL/min/1.73 m² (interquartile range 33.86-93.14). Over 12 months, telitacicept 80 mg weekly was associated with a trend toward greater proteinuria reduction (-51.52% versus -33.31%, P = .081) and a favorable change in renal function (+1.77 versus -4.06 mL/min/1.73 m², P = .008). The early-start subgroup showed greater benefits than the late-start subgroup. In an exploratory analysis of patients with eGFR <35 mL/min/1.73 m² (n = 7 each), telitacicept treatment yielded a sustained reduction in UPCR (-48.83% versus +9.68%) and a stable mean annualized eGFR slope (+0.77 versus -8.88 mL/min/1.73 m²) over 12 months. No severe adverse events occurred with telitacicept, versus one in controls.Conclusions
Our study supports the potential efficacy of low-dose telitacicept in reducing proteinuria and stabilizing eGFR in IgAN. Its clinical benefits were more pronounced when initiated early after diagnosis. Furthermore, in IgAN patients with severe renal impairment, telitacicept may yield better outcomes for proteinuria reduction and eGFR preservation than conventional treatment. These advantages position low-dose telitacicept as a potentially effective treatment strategy, though larger prospective studies are warranted.
Related
- Preliminary evaluation of the efficacy and safety of telitacicept in children with IgA nephropathy
- Efficacy and Safety of Moderate-Dose Glucocorticoids with Tacrolimus in High-Risk Membranous Nephropathy: A Real-World Comparison of Three Immunosuppressive Regimens.
- Comparative efficacy and safety of targeted disease-modifying therapies in adults with primary IgA nephropathy: a systematic review and network meta-analysis
- Optimizing Indocyanine Green Fluorescence Cholangiography in Laparoscopic Cholecystectomy: A Systematic Review of Randomized Controlled Trials on Dose, Timing, Route, Efficacy, and Safety
- 563 Updated safety and efficacy of AN4005, an oral small-molecule PD-L1 inhibitor, in advanced solid tumors: phase I dose-escalation and expansion
BibTeX
@article{liu2026efficacy,
title = {{Efficacy and safety of low-dose telitacicept in IgA nephropathy: a real-world study.}},
author = {Chenxi Liu and Juanyong Zhao and Ming Xia and Xinyan Fan and Xunzi Tang and Xiaomiao Hao and Lili Wan and Bin Len and Di Liu and Haiyang Liu and Linshan Zhou and Xia Tan and Hong Liu},
journal = {Clinical kidney journal},
year = {2026},
month = oct,
doi = {10.1093/ckj/sfag312},
url = {https://europepmc.org/article/MED/42899115},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Efficacy and safety of low-dose telitacicept in IgA nephropathy: a real-world study.
AU - Chenxi Liu
AU - Juanyong Zhao
AU - Ming Xia
AU - Xinyan Fan
AU - Xunzi Tang
AU - Xiaomiao Hao
AU - Lili Wan
AU - Bin Len
AU - Di Liu
AU - Haiyang Liu
AU - Linshan Zhou
AU - Xia Tan
AU - Hong Liu
PY - 2026
DA - 2026/10/12
JO - Clinical kidney journal
DO - 10.1093/ckj/sfag312
UR - https://europepmc.org/article/MED/42899115
AB - Background Immunoglobulin A nephropathy (IgAN) represents one of the most common causes of primary glomerulonephritis with unmet clinical needs. This study evaluates the efficacy and safety of telitacicept in patients with IgAN.Methods This real-world study included 38 biopsy-proven IgAN patients with baseline estimated glomerular filtration rate (eGFR) >10 mL/min/1.73 m² and urine protein-to-creatinine ratio (UPCR) >440 mg/g. Nineteen patients received weekly telitacicept 80 mg (telitacicept group), divided into early-start (telitacicept treatment initiated within 6 months after diagnosis) and late-start (>6 months) subgroups. The other 19, diagnosed during the same period but not receiving telitacicept, served as controls. Clinical data were collected over 12 months. Safety was evaluated.Results Baseline characteristics were comparable between groups. In the telitacicept group, median UPCR was 1715.98 mg/g (interquartile range 1281.63-2892.11) and median eGFR was 45.45 mL/min/1.73 m² (interquartile range 33.86-93.14). Over 12 months, telitacicept 80 mg weekly was associated with a trend toward greater proteinuria reduction (-51.52% versus -33.31%, P = .081) and a favorable change in renal function (+1.77 versus -4.06 mL/min/1.73 m², P = .008). The early-start subgroup showed greater benefits than the late-start subgroup. In an exploratory analysis of patients with eGFR <35 mL/min/1.73 m² (n = 7 each), telitacicept treatment yielded a sustained reduction in UPCR (-48.83% versus +9.68%) and a stable mean annualized eGFR slope (+0.77 versus -8.88 mL/min/1.73 m²) over 12 months. No severe adverse events occurred with telitacicept, versus one in controls.Conclusions Our study supports the potential efficacy of low-dose telitacicept in reducing proteinuria and stabilizing eGFR in IgAN. Its clinical benefits were more pronounced when initiated early after diagnosis. Furthermore, in IgAN patients with severe renal impairment, telitacicept may yield better outcomes for proteinuria reduction and eGFR preservation than conventional treatment. These advantages position low-dose telitacicept as a potentially effective treatment strategy, though larger prospective studies are warranted.
SN - 2048-8505
SN - 2048-8513
ER -